Member Info for Toyin

Net, i'm sure you make sense to yourself and i'm very happy for you. Back on earth, you couldn’t have been more wrong.

The share price is temporary and I couldn’t care less, what I care about is rubbish acquisitions, dilution, £4m SD fund raise, more dilution, can kicking, lies etc, etc. So whilst you were blowing smoke up Ashman’s backside along with the other muppets that have now left, I (along with shy, TW, etc) was busy having comms with the authorities and asking them to look into the running of the company, trying to look after my investment, whilst you and others were having a pop and taking pleasure in pointing out how pathetic and sad we naysayers were.

I would much rather be at 8p with Rachel and Alyson than at 20p and still have SA at the helm. Short term pain long term gain.

talking of "honesty" and "morally" oh, and pumping! this didn't age well did it:

netcurtains

posted in: sbtx

posts: 1,443

re: bazaar29 dec 2025 09:46

if we analyse what went wrong for the anti-ashman coup - basically those that presented it had a semi-reasonable case (the share price has tanked) but because their gave off such a air of superiority and a vague unpleasentness they lost the sympathy of their audience. investors did not warm to them. in short they failed to give a sense of optimisim of how wonderful things would be if there was a change at the top. the bottom line is investors want a good story not a bad story. the naysayers managed to give a vaguely bad story but failed totally to give a good story. hence people failed to back them in any numbers.

so what next?

cheer on ashman - the ball is now firmly in your hands - run with it mate - get this share into orbit. steam train coming down the lines!

end

ps, i think you will find the naysayers didn't fail, the ceo has gone!

now, can we keep it to sbtx and stop blocking the board with ******!

Shrek, I think he is 100% correct, what didn't you agree with in the article?

Cant blame the guy, shrewd move IMO.

Martin, from memory it’s a guy called Jan Charlesworth at Gravita.

Martin, I am sure the auditors insurers will be on standby.

Hi Bazza, yes, I’m sure they want this done asap but I'm more than happy for them to take their time and do it right. Looking forward to leaving the Ashman legacy well and truly behind us.

Shy, my take is I think it is going to be a close call so they are airing on the side of caution.

FYI.

Dear XXX,

The Company is hoping to conclude the investigation in as timely a manner as possible and the results will feed into the Board’s investigation. The underlying aim is the investigation is thorough so that the figures we issue in the HY results and restated FY25 results are set in stone; that shareholders can be wholly confident that there will be no further adjustments so we can draw a line on this situation and move forwards.

We will provide more information on the financials in the HY results, but note that we will be seeking to recover some of the costs of the investigation.

Finally, with respect to the suspension of shares, we were obliged to inform the AIM authorities as soon as we were aware of the results deadline situation, hence the announcement last week. However, suspension of trading in this case is only triggered if HY results are not issued by the deadline of 31 March 2026.

With kind regards,

SkinBioTherapeutics IR team

Thank you for the update Aquae, much appreciated and encouraging.

Hi Bazza, yes, hopefully we can move forward now and see the fruits of the Croda partnership. It’s all very sad what has transpired and yes there were many red flags, but I have to say, I never thought they would turn out to be as bad as cooking the books. Desperate men do desperate thing.

Tiny, I had no problem with anyone who thought the BOD were doing a good job, we all see things differently, I just found the personal attacks and pack mentality tragic from those pumpers who have now left, hopefully some karma will come their way.

Let’s hope your partner is correct, she certainly had Ashman’s number long before I did and I agree with her reasoning for staying invested. For me nothing has changed, I was always here for Croda not the BOD, some short term pain for long term gain.

Net, if I was negative the stock I wouldn’t hold it. But whilst we are on the subject, I was negative about the BOD quite a while back as I reported them to the FCA, FRC & AIM regulation, as did Shychap, TW and some other investors I know, I also remember you and others taking great pleasure in berating us for “moaning” and we were told to get behind the BOD or sell up. I hope that the actions of the above mentioned people is part of the reason we have seen the downfall of the people involved and they get the full punishment they deserve. I see your moronic friends you agreed with at the time have now left the discussion which is no bad thing.

For clarification, I am positive on the stock, I was negative on the BOD, it looks like we now have a couple of good additions who are sorting the situation out.

Ps, you posted your reply on the wrong thread.

Net, stop with the knicker wetting. Sorry for going over old ground but let’s have a refresher.

1) Dermatonics and Bio-Tech Solutions are operating as reported at FY25 (audited revenues of £2.20m and £1.38m respectively) and both are trading at cash breakeven. These businesses are trading in line with the current Board's expectations for FY26.

Importantly it states “current” board’s expectations.

2) If SD is doing poorly on sales, let’s say 1 box of each per week per store, that’s circa £24k a month coming in and nothing going out. If they are doing enough for us to be having to order more stock, happy days. Either way it’s a win/win in our current situation.

3) Zenakine has launched in Europe and Asia, so royalties will be starting to flow.

4) Cash burn is high for the month but we don’t know why, maybe FRP wanted upfront, maybe a def con was paid. What I do know is we haven’t suddenly become a £5m a year cash guzzler.

The suspension is an inconvenience but the timing is what the timing is, if this had been uncovered earlier it would have been a different story, but it wasn’t. I would rather it be done right and have a clean bill of health. If I was the interim CEO I would have demanded an external investigation before I agreed to join

Nothing has changed, sell off is nuts.

Net, Croda Beauty LATAM is the Latin American division of Croda Beauty, a global leader in supplying high-performance, sustainable ingredients and formulation expertise for the personal care and cosmetics industry

https://www.croda.com/en-gb/about-us/where-we-operate/latin-america

Https://www.instagram.com/p/DWFCVNMkc-W/

Net, considering you only have a few, you seem to be getting a bit frustrated over nothing.

I like the fact that they mention 10% sales increase and the very first ingredient mentioned is Zenakine, a subliminal stimuli maybe?

From Croda’s annual report:

Innovation remains central to Croda’s differentiation. We continue to focus on innovating at the top of our portfolio, while actively managing and, where appropriate, rationalising less differentiated products. The Board has reviewed the innovation pipeline and remains confident in its strength, supported by unrivalled claims data and solutions often tailored to individual customers. New product launches in 2025, such as Zenakine, a naturally derived neuroactive ingredient developed in partnership with a start-up, to address the effects of stress on skin, demonstrate our continued ability to deliver solutions that matter. New process innovation includes our investment with our pharma facility at Leek, which supported the launch of Super RefinedTM Poloxamer 188.

We have ramped up the development of new ingredients with sales increasing by 10% at constant currency. Launches included:

Zenakine, an active which enhances skin’s resistance to physical and emotional stress, thereby reducing skin fatigue and premature ageing, with customer launches in Europe and Asia.

Our customer engagement continues to be strong on sustainability topics, demonstrating our established position in decarbonisation and fast-emerging leadership in reducing water use impact.

NatrineoTM CR8*, KeraBioTMK31 and ZenakineTM* are all examples of our latest award winning innovation, with strong sustainability credentials such as 100% natural content, lower GHG emissions, biodegradability, more sustainable sourcing or produced via biotechnology. They have been well received by our customers and the wider market.

Launched a number of innovative products including Kerabio, Natrineo CR8, Zenakine, Squalene and Poloxamer, resulting in strong interest from our customers.

No.

Aquae, agreed, thats why I included it. I discounted it by 50% due to current uncertainty.

Fair comment Ed, all I am going off is the fact that Singers forecast for FY26 is £6.2m which concurs with the last line of the rns and management said both companies are trading in line.

* Market expectations for the year ending 30 June 2026 were revenue of £6.2m and adjusted EBITDA of £0.7 million.

Net, you seem to have a lot of feelings about things and make a few assumptions. Its probably best to wait until we see HY results. I was just replying with some facts and pointing out the BOD have a lot on their plate at the moment, so statistically this situation could quite easily be an outlier.

Net, let's look at what we know from the last rns 16/2/26.

As of 13/2/26 we had £2.92m cash.

Dermatonics & BTS businesses are trading in line with the current Board's expectations for FY26.

Direct product sales of AxisBiotix™ are reported correctly in FY25.

As a result of the Board's Investigation and the subsequent expected removal of the FY25 Accrued Royalty Income, the Board now anticipates that the results for the year ended 30 June 2026 will be significantly below current market expectations.

So we can confidently say that those statements above are correct.

Singers have NPV of:

Derma 3p

BTS 3p

Axis ex SD 1p

SD 2p

Zenakine 19p

Now if we half Zenakine and forget SD that gives us NPV of 16.5p.

We also know from Croda’s results the following:

"Zenakine, an active which enhances skin’s resistance to physical and emotional stress, thereby reducing skin fatigue and premature ageing, with customer launches in Europe and Asia.”

So we know royalties have started flowing.

Regarding the delay of news as you put it, our new CEO only joined sixteen days ago, she will want to check, double check, triple check and put some belts and braces on the half year results before they go out. The half year report last year came out on the 26th March, this year we have a new CEO that has been in situ for just over two weeks, an ex CEO who has cooked the books and an external investigation to clear the decks. I think Alyson and Rachel have a big task on their hands and deserve some time and space.

I believe the "significantly below current market expectations" has been put in to kitchen sink the job and isn't strictly correct, for two reasons.

1, The £770k will have to be removed but this doesn't impact the cash position it is just an accounting procedure to right the wrong of FY25, so will effect forecasts for FY26 by £770k, ergo we have a material miss.

2, Nobody knows how much in sales we will receive from Croda up to the end of June 2026.

I am not panicking and by the looks of it neither is MD.